Cambridge and AndzonBio2 Unite to Fight Neuroinflammation

PARIS and CAMBRIDGE, England – May 13, 2026 – A new strategic collaboration between French neuroscience company AndzonBio2 and the University of Cambridge is set to pioneer a new class of drugs targeting neuroinflammation, a condition increasingly understood as a central culprit in devastating brain diseases like Alzheimer's, Parkinson's, and ALS.

The partnership, which includes the University’s ALBORADA Drug Discovery Institute (ADDI) and its commercialization arm, Cambridge Enterprise, aims to turn cutting-edge academic science into urgently needed therapies. The announcement brings a new ray of hope to a field grappling with the health of over 3 billion people worldwide affected by neurological disorders—a figure that underscores the profound and growing global health crisis.

The Next Frontier: Targeting the Brain's 'Smoldering Fire'

For decades, the prevailing view of neurodegenerative diseases focused on toxic protein build-ups, such as amyloid plaques in Alzheimer's. While still critical, a paradigm shift is underway in neuroscience, with researchers now focusing on the role of chronic, low-grade inflammation in the brain. Unlike the helpful, short-term inflammation that fights infection, this persistent 'smoldering fire' is believed to be a key biological driver that accelerates neuronal damage and disease progression.

This makes neuroinflammation one of the most promising therapeutic targets for creating truly disease-modifying treatments, rather than therapies that only manage symptoms. The collaboration between AndzonBio2 and Cambridge aims to develop a 'first-in-class' therapeutic program, suggesting a novel approach to modulating the specific biological pathways that fuel this chronic inflammation.

The landscape for such treatments is becoming increasingly active, with researchers globally investigating targets like the NLRP3 inflammasome and other key signaling pathways. However, the field remains challenging, with high failure rates for drugs targeting central nervous system disorders. This new alliance hopes to break that trend by combining deep biological understanding with agile drug development.

A Powerhouse Partnership of Science and Strategy

The collaboration represents a model of modern drug discovery, braiding together the distinct strengths of academia and a specialized biotechnology firm. The ALBORADA Drug Discovery Institute, funded by Alzheimer's Research UK and the ALBORADA Trust, serves as a crucial bridge between foundational academic research and the rigorous demands of pharmaceutical development. As part of a UK-wide Drug Discovery Alliance, ADDI has a formidable track record, having investigated over 80 potential drug targets for dementia.

Professor John Skidmore, Chief Scientific Officer of ADDI, emphasized the collaborative spirit. "We are delighted to collaborate with AndzonBio2 on this promising project," he stated. "This partnership exemplifies our commitment to translating cutting-edge neuroscience into impactful therapies. AndzonBio2 brings a focused expertise in neuroinflammation and drug development that will be instrumental in driving this promising programme forward."

Facilitating this translation is Cambridge Enterprise, the university's innovation arm responsible for transforming Cambridge research into global impact. By managing the intellectual property and granting AndzonBio2 an exclusive option to license the resulting discoveries, Cambridge Enterprise provides the commercial framework necessary to attract investment and move a potential therapy from the lab toward the clinic.

AndzonBio2's Focused Bet on a Complex Problem

For AndzonBio2, this partnership is a cornerstone of its corporate strategy. The company, which emerged from stealth mode in October 2025 with €3 million in seed funding from AdBio Partners and Inserm Transfert, was purpose-built to tackle neuroinflammation. Its business model is designed to be nimble, searching across Europe for the most promising scientific projects and building a focused portfolio.

This collaboration is a prime example of its model in action. Rather than building vast internal discovery labs, AndzonBio2 is leveraging the world-class neuroscience capabilities at Cambridge to accelerate its mission. This lean and targeted approach allows a relatively new company to take on one of medicine's most complex challenges.

Loic Lhuillier, CEO of AndzonBio2, expressed his enthusiasm for the joint effort. "We are thrilled to enter this collaboration with the ADDI at Cambridge. Neuroinflammation is at the core of many severe brain diseases and new therapeutic solutions are urgently needed," he said. "By combining our complementary strengths, we have a unique opportunity to accelerate the development of a highly innovative therapeutic approach with the potential to change the treatment landscape for patients."

Addressing a Colossal Unmet Need

The urgency Lhuillier speaks of is backed by sobering statistics. Neurological conditions are now the leading cause of ill health and disability globally. The burden of these diseases, measured in years of healthy life lost, has surged by 18% since 1990. For diseases like Alzheimer's, the number of affected individuals is projected to surpass 80 million by 2040.

Despite this staggering need, the path to new treatments has been fraught with failure, with some estimates putting the failure rate for Alzheimer's drug development as high as 95%. This history of setbacks has highlighted the need for entirely new therapeutic strategies, moving away from well-trodden paths and toward novel biological targets like those central to neuroinflammation.

The World Health Organization has issued a call for urgent global action to prioritize brain health and address the vast gaps in care and treatment, particularly in low- and middle-income countries. Initiatives like the one between AndzonBio2 and Cambridge are a direct response to this call, representing a calculated and strategic effort to finally turn the tide against a class of diseases that has long eluded medical science.